CoChat
Sign Up
Cited by 323

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease

Brakedal, Brage, Dölle, Christian, Riemer, Frank, Ma, Yilong, Nido, Gonzalo S., Skeie, Geir Olve, Craven, Alexander R., Schwarzlmüller, Thomas, Brekke, Njål, Diab, Joseph, Sverkeli, Lars, Skjeie, Vivian, Varhaug, Kristin, Tysnes, Ole-Bjørn, Peng, Shichun, Haugarvoll, Kristoffer, Ziegler, Mathias, Grüner, Renate, Eidelberg, David, Tzoulis, Charalampos·2022·Cell Metabolism
DOI 10.1016/j.cmet.2022.02.001
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2022.02.001

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 65

  1. Akie, 2015, OXPHOS-mediated induction of NAD+ promotes complete oxidation of fatty acids and interdicts non-alcoholic fatty liver disease, PLoS One, 10, e0125617, 10.1371/journal.pone.0125617 · DOI
  2. Asanuma, 2006, Network modulation in the treatment of Parkinson’s disease, Brain, 129, 2667, 10.1093/brain/awl162 · DOI
  3. Ashburner, 2000, Gene ontology: tool for the unification of biology. The Gene Ontology Consortium, Nat. Genet., 25, 25, 10.1038/75556 · DOI · Paper page
  4. Athauda, 2015, The ongoing pursuit of neuroprotective therapies in Parkinson disease, Nat. Rev. Neurol., 11, 25, 10.1038/nrneurol.2014.226 · DOI
  5. Bieganowski, 2004, Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans, Cell, 117, 495, 10.1016/S0092-8674(04)00416-7 · DOI · Paper page
  6. Boenzi, 2018, Biomarkers for mitochondrial energy metabolism diseases, Essays Biochem., 62, 443, 10.1042/EBC20170111 · DOI
  7. Braidy, 2020, NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis, Exp. Gerontol., 132, 110831, 10.1016/j.exger.2020.110831 · DOI
  8. Conze, 2016, Safety assessment of nicotinamide riboside, a form of vitamin B3, Hum. Exp. Toxicol., 35, 1149, 10.1177/0960327115626254 · DOI
  9. de Rijk, 2000, Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group, Neurology, 54, S21
  10. Deelchand, 2015, Quantification of in vivo 31P NMR brain spectra using LCModel, NMR Biomed., 28, 633, 10.1002/nbm.3291 · DOI
  11. Dias, 2013, The role of oxidative stress in Parkinson’s disease, J. Parkinsons Dis., 3, 461, 10.3233/JPD-130230 · DOI · Paper page
  12. Dollerup, 2018, A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects, Am. J. Clin. Nutr., 108, 343, 10.1093/ajcn/nqy132 · DOI · Paper page
  13. Edden, 2014, Gannet: a batch-processing tool for the quantitative analysis of gamma-aminobutyric acid–edited MR spectroscopy spectra, J. Magn. Reson. Imaging, 40, 1445, 10.1002/jmri.24478 · DOI
  14. Espay, 2017, Precision medicine for disease modification in Parkinson disease, Nat. Rev. Neurol., 13, 119, 10.1038/nrneurol.2016.196 · DOI
  15. Flønes, 2018, Neuronal complex I deficiency occurs throughout the Parkinson’s disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage, Acta Neuropathol., 135, 409, 10.1007/s00401-017-1794-7 · DOI
  16. Gillis, 2010, Gene function analysis in complex data sets using ErmineJ, Nat. Protoc., 5, 1148, 10.1038/nprot.2010.78 · DOI
  17. Gonzalez-Hunt, 2021, DNA damage and repair in Parkinson’s disease: recent advances and new opportunities, J. Neurosci. Res., 99, 180, 10.1002/jnr.24592 · DOI
  18. Gooch, 2017, The burden of neurological disease in the United States: a summary report and call to action, Ann. Neurol., 81, 479, 10.1002/ana.24897 · DOI
  19. Guarino, 2019, Nicotinamide and NAFLD: is there nothing new under the sun?, Metabolites, 9, 180, 10.3390/metabo9090180 · DOI
  20. Habeck, 2005, A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis, Neural Comput., 17, 1602, 10.1162/0899766053723023 · DOI
  21. Han, 2020, Nicotinamide riboside protects noise-induced hearing loss by recovering the hair cell ribbon synapses, Neurosci. Lett., 725, 134910, 10.1016/j.neulet.2020.134910 · DOI
  22. Harlan, 2020, Evaluation of the NAD+ biosynthetic pathway in ALS patients and effect of modulating NAD+ levels in hSOD1-linked ALS mouse models, Exp. Neurol., 327, 113219, 10.1016/j.expneurol.2020.113219 · DOI
  23. Hattori, 1991, Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson’s disease, Ann. Neurol., 30, 563, 10.1002/ana.410300409 · DOI
  24. Hirsch, 2009, Neuroinflammation in Parkinson’s disease: a target for neuroprotection?, Lancet Neurol., 8, 382, 10.1016/S1474-4422(09)70062-6 · DOI · Paper page
  25. Jadavji, 2015, Methylenetetrahydrofolate reductase deficiency alters levels of glutamate and γ-aminobutyric acid in brain tissue, Mol. Genet. Metab. Rep., 3, 1
  26. Jenner, 2003, Oxidative stress in Parkinson’s disease, Ann. Neurol., 53, S26, 10.1002/ana.10483 · DOI · Paper page
  27. Kalia, 2015, Parkinson’s disease, Lancet, 386, 896, 10.1016/S0140-6736(14)61393-3 · DOI · Paper page
  28. Katsyuba, 2020, NAD+ homeostasis in health and disease, Nat. Metab., 2, 9, 10.1038/s42255-019-0161-5 · DOI · Paper page
  29. Ko, 2014, Network modulation following sham surgery in Parkinson’s disease, J. Clin. Invest., 124, 3656, 10.1172/JCI75073 · DOI
  30. Lamb, 2020, Resistance training increases muscle NAD+ and NADH concentrations as well as NAMPT protein levels and global sirtuin activity in middle-aged, overweight, untrained individuals, Aging (Albany, NY), 12, 9447, 10.18632/aging.103218 · DOI · Paper page
  31. Lehtonen, 2016, FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders, Neurology, 87, 2290, 10.1212/WNL.0000000000003374 · DOI · Paper page
  32. Lehtonen, 2019, Dysfunction of cellular proteostasis in Parkinson’s disease, Front. Neurosci., 13, 457, 10.3389/fnins.2019.00457 · DOI
  33. Lozza, 2004, Executive processes in Parkinson’s disease: FDG-PET and network analysis, Hum. Brain Mapp., 22, 236, 10.1002/hbm.20033 · DOI
  34. Lu, 2014, Intracellular redox state revealed by in vivo (31) P MRS measurement of NAD(+) and NADH contents in brains, Magn. Reson. Med., 71, 1959, 10.1002/mrm.24859 · DOI
  35. Martens, 2018, Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults, Nat. Commun., 9, 1286, 10.1038/s41467-018-03421-7 · DOI · Paper page
  36. Mollenhauer, 2020, Validation of serum neurofilament light chain as a biomarker of Parkinson’s disease progression, Mov. Disord., 35, 1999, 10.1002/mds.28206 · DOI
  37. Monaco, 2019, RNA-seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types, Cell Rep., 26, 1627, 10.1016/j.celrep.2019.01.041 · DOI · Paper page
  38. Mukherjee, 2017, Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration, Hepatology, 65, 616, 10.1002/hep.28912 · DOI
  39. Mure, 2011, Parkinson’s disease tremor-related metabolic network: characterization, progression, and treatment effects, Neuroimage, 54, 1244, 10.1016/j.neuroimage.2010.09.028 · DOI
  40. Mure, 2012, Improved sequence learning with subthalamic nucleus deep brain stimulation: evidence for treatment-specific network modulation, J. Neurosci., 32, 2804, 10.1523/JNEUROSCI.4331-11.2012 · DOI
  41. Near, 2015, Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain, Magn. Reson. Med., 73, 44, 10.1002/mrm.25094 · DOI
  42. Niethammer, 2012, Metabolic brain networks in translational neurology: concepts and applications, Ann. Neurol., 72, 635, 10.1002/ana.23631 · DOI
  43. Niethammer, 2018, Gene therapy reduces Parkinson’s disease symptoms by reorganizing functional brain connectivity, Sci. Transl. Med., 10, eaau0713, 10.1126/scitranslmed.aau0713 · DOI
  44. Okur, 2020, Short-term NAD+ supplementation prevents hearing loss in mouse models of Cockayne syndrome, NPJ Aging Mech. Dis., 6, 1, 10.1038/s41514-019-0040-z · DOI
  45. Park, 2016, Regulation of histone acetylation by autophagy in Parkinson disease, J. Biol. Chem., 291, 3531, 10.1074/jbc.M115.675488 · DOI
  46. Patro, 2017, Salmon provides fast and bias-aware quantification of transcript expression, Nat. Methods, 14, 417, 10.1038/nmeth.4197 · DOI · Paper page
  47. Peeters, 2019, 3D 31P MR spectroscopic imaging of the human brain at 3 T with a 31P receive array: an assessment of 1H decoupling, T1 relaxation times, 1H–31P nuclear Overhauser effects and NAD+, NMR Biomed., 34, e4169, 10.1002/nbm.4169 · DOI
  48. Peng, 2014, Characterization of disease-related covariance topographies with SSMPCA toolbox: effects of spatial normalization and PET scanners, Hum. Brain Mapp., 35, 1801, 10.1002/hbm.22295 · DOI
  49. Petrillo, 2020, Systemic activation of Nrf2 pathway in Parkinson’s disease, Mov. Disord., 35, 180, 10.1002/mds.27878 · DOI
  50. Pietrocola, 2015, Acetyl coenzyme A: a central metabolite and second messenger, Cell Metab., 21, 805, 10.1016/j.cmet.2015.05.014 · DOI · Paper page
  51. Purvis, 2017, OXSA: an open-source magnetic resonance spectroscopy analysis toolbox in MATLAB, PLoS One, 12, e0185356, 10.1371/journal.pone.0185356 · DOI
  52. Ren, 2018, Unveiling a hidden 31P signal coresonating with extracellular inorganic phosphate by outer-volume-suppression and localized 31P MRS in the human brain at 7T, Magn. Reson. Med., 80, 1289, 10.1002/mrm.27121 · DOI
  53. Rocha, 2015, Insights into neuroinflammation in Parkinson’s disease: from biomarkers to anti-inflammatory based therapies, BioMed Res. Int., 2015, 628192, 10.1155/2015/628192 · DOI
  54. Schapira, 1989, Mitochondrial complex I deficiency in Parkinson’s disease, Lancet, 1, 1269, 10.1016/S0140-6736(89)92366-0 · DOI
  55. Schindlbeck, 2018, Network imaging biomarkers: insights and clinical applications in Parkinson’s disease, Lancet Neurol., 17, 629, 10.1016/S1474-4422(18)30169-8 · DOI
  56. Schöndorf, 2018, The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson’s disease, Cell Rep., 23, 2976, 10.1016/j.celrep.2018.05.009 · DOI · Paper page
  57. Soneson, 2015, Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences, F1000Res., 4, 1521, 10.12688/f1000research.7563.1 · DOI · Paper page
  58. Sorrentino, 2017, Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity, Nature, 552, 187, 10.1038/nature25143 · DOI · Paper page
  59. Spetsieris, 2013, Identification of disease-related spatial covariance patterns using neuroimaging data, J. Vis. Exp., 50319
  60. Starcevic, 2004, Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1), J. Biol. Chem., 279, 28393, 10.1074/jbc.M402513200 · DOI
  61. Tang, 2013, Metabolic network as a progression biomarker of premanifest Huntington’s disease, J. Clin. Invest., 123, 4076, 10.1172/JCI69411 · DOI
  62. Teune, 2013, Validation of parkinsonian disease-related metabolic brain patterns, Mov. Disord., 28, 547, 10.1002/mds.25361 · DOI
  63. Toker, 2021, Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain, Mol. Neurodegener., 16, 31, 10.1186/s13024-021-00450-7 · DOI
  64. Wu, 2013, Metabolic brain network in the Chinese patients with Parkinson’s disease based on 18F-FDG PET imaging, Parkinsonism Relat. Disord., 19, 622, 10.1016/j.parkreldis.2013.02.013 · DOI
  65. Xie, 2019, Nicotinamide ribose ameliorates cognitive impairment of aged and Alzheimer’s disease model mice, Metab. Brain Dis., 34, 353, 10.1007/s11011-018-0346-8 · DOI

Cited by

Sorted by citations

See all 323

Metadata

Authors
Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., Sverkeli, L., Skjeie, V., Varhaug, K., Tysnes, O.-B., Peng, S., Haugarvoll, K., Ziegler, M., Grüner, R., Eidelberg, D., & Tzoulis, C.
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2022-03
Volume
34
Issue
3
Pages
396-407.e6
ISSN
1550-4131
DOI
10.1016/j.cmet.2022.02.001
Cited by
323
References
10
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. https://app.cochat.ai/papers/10.1016/j.cmet.2022.02.001
The paper
Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., Sverkeli, L., Skjeie, V., Varhaug, K., Tysnes, O.-B., Peng, S., Haugarvoll, K., Ziegler, M., Grüner, R., Eidelberg, D., & Tzoulis, C. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism. https://doi.org/10.1016/j.cmet.2022.02.001